Global Glaucoma Surgery Devices Market Size, Share, Growth & Trends Report Segmented by Product (Drainage Devices, Traditional Systems, Implants, Stents), Surgery Type (MIGS, Conventional, Laser), End User (Hospitals, Clinics, ASCs, Ophthalmic Clinics) & Regional Forecast to 2031

Glaucoma Surgical Devices are medical and implantable instruments designed to lower eye pressure and help preserve the optic nerve from permanent damage. These devices facilitate controlled aqueous humor outflow or reduce its production when medications or laser therapies are insufficient. The devices can include common surgical instruments, devices that help to drain the fluid, also known as glaucoma drainage devices, implants such as value devices, tubes, and minimally invasive surgery (MIGS) systems. Devices used to maintain long-term control over intraocular pressure, reduce reliance on topical medications and preserve visual acuity are used in hospitals, outpatient clinics and ambulatory surgical centers for treating patients with different types and stages of glaucoma.

Rising glaucoma prevalence and aging population to propel market demand

The increasing prevalence of glaucoma and the imminent increase in the size of the global elderly population are primarily responsible for growth of the glaucoma surgery devices market as they affect both the number of patients to be treated and the need for effective, long-term treatment methods. Glaucoma is the leading cause of preventable blindness in the world; its incidence is likely to continue to increase due to population growth, aging, and improved diagnostic capacity. According to the Glaucoma Research Foundation, glaucoma continues to be a leading cause of blindness worldwide, responsible for 9% to 12% of cases, affecting approximately 5.9 million people; and as of 2020, approximately 80 million people worldwide had glaucoma, with 60 million affected by open-angle glaucoma. Since glaucoma often progresses silently until significant vision loss occurs, a growing number of patients are being diagnosed at moderate to advanced stages, where surgical intervention becomes clinically necessary.

The most important risk factor for developing glaucoma is age. The incidence of primary open angle glaucoma rises significantly after the age of 60; with a rapidly growing global elderly adult population, particularly in regions such as North America, Europe, and Asia-Pacific, the burden of glaucoma will likely be immediate and significant. Older patients also tend to have comorbidities and cannot tolerate long-term drug therapy; therefore, they will rely more heavily on surgical treatments that provide stable intraocular pressure (IOP) control. As a result, the growth of this demographic group is influencing eye care professionals to use surgical devices that produce predictable results and lessen the extent of the progression of the disease.

The growing number of older individuals contributes to the increased need for managing chronic eye disease through more effective healthcare delivery systems. Long-term patients on glaucoma medications may experience non-compliance issues due to inability to use eye drops accurately, damage to the ocular surface, and financial burden caused by continuing costs of medication, particularly with older patients. Therefore, there has been a change in preference by clinicians to utilize surgical methods of treating glaucoma, most notably, the use of MIGS devices, that can be used earlier in their treatment. Compared with other surgical methods of treating glaucoma, MIGS devices generally have fewer risks associated with their use, less recovery time, and are more likely to be used in conjunction with cataract surgery (which is prevalent among older adults).

The increasing prevalence of glaucoma will continue to drive an increase in the number of glaucoma screenings and early detection of patients prior to surgical intervention; hence, creating a larger pool of patients for clinicians to potentially treat with a surgical intervention. As knowledge regarding glaucoma and life expectancy continues to improve, more patients will be interested in achieving and maintaining functional vision and quality of life for a longer period after surgery. Because of these trends, there is a significant increase in the demand for advanced surgical devices for the treatment of glaucoma, which stimulates invention and new techniques, increases the volume of procedures performed, and continues to ensure the overall continued future growth of the glaucoma surgery device market globally.

To learn more about this report, download the PDF brochure

Technological advancements in MIGS and next-generation devices of care is driving the market growth

The growth of the global glaucoma surgery device market can be attributed largely to technological advancements in MIGS and the emergence of next-generation glaucoma devices that are fundamentally changing the way in which glaucoma is treated throughout the disease continuum. Traditional forms of glaucoma surgery are generally effective; however, they also carry a higher risk of complications, require longer recovery times, and are more complex to perform than MIGS. MIGS technologies eliminate the obstacles by providing safer and less invasive alternatives to achieve a clinically significant reduction in IOP along with improved patient outcomes. This allows for surgical interventions to be available to more patients than before.

MIGS devices like microstents, trabecular meshwork bypass devices, subconjunctival drainage implants, have greatly increased the surgical treatment population by allowing for earlier intervention in cases of mild/moderate glaucoma. Because of their non-invasive design, MIGS create less trauma to surrounding tissues in comparison to traditional procedures, resulting in relatively fewer postoperative complications and shorter recovery times. Therefore, patients and surgeons have historically considered surgery as a last resort; however, today, surgery may be considered as a viable adjunct to or alternative to long-term medical treatment for patients with glaucoma.

Innovations in devices for the next generation continue to spur the adoption of these new treatments. Implant materials have advanced significantly enhancing biocompatibility of implants, with designs that minimize obstructions or migration, and drug-eluting implants offer attractions that are an addition to combining mechanical methods of reducing IOP with localized pharmacological treatment. Improved long-term efficacy of these implantations ultimately reduces reliance on daily eye drops, which are a key impediment to effective management of chronic glaucoma. The continued development of devices designed for cataract surgery has also led to an increasing number of procedural synergies, particularly among the older patient population, which has led to greater procedural volume.

Technological advances in surgical visualization, including intraoperative imaging and precision delivery systems, have also led to greater procedural accuracy and reproducibility, while reducing the learning curve for newer techniques, thus encouraging greater adoption of these techniques across diverse clinical environments. Additionally, new smart and connected glaucoma devices have made available real-time monitoring of IOP, paving the way for new options for the tailoring of postoperative care and long-term management of the disease.

On the market side, continuous technological innovation is resulting in increased competition among device manufacturers, expanding the product pipeline available to clinicians, and attracting additional investment in continuing research and development. The recent approval by regulatory agencies of several new MIGS devices has further validated their clinical efficacy and expedited their introduction into the marketplace. Collectively, these advances are transforming glaucoma care by enhancing safety, expanding the clinical indications for treatment, and improving overall patient care, thereby supporting ongoing growth in this area of the medical marketplace.

Growth strategies adopted by players to establish their foothold in the market

Players operating in this market are adopting various growth strategies such as new product launches and approvals, acquisitions, investments, and strategic partnerships and collaborations to garner market share. For instance,

• In October 2025, Y.ora Vision and Eyexora Global partnered with the Singapore Eye Research Institute to advance a next-generation MIGS platform (YRA-01) for treating mild-to-severe open-angle glaucoma. The implant-free, handheld device enables multiple trabeculotomies in a single, short procedure, offering surgeons greater control, flexibility, and effective intraocular pressure reduction without permanent implants
• In September 2025, New World Medical launched the Ahmed ClearPath ST, a new nonvalved glaucoma drainage device featuring a smaller tube lumen to improve pressure control and surgical flexibility. The device expands the Ahmed ClearPath portfolio by enabling enhanced safety, personalized treatment options, and easier implantation for glaucoma specialists
• In July 2025, BVI debuted Leos, the first FDA-cleared laser endoscopy system with advanced digital visualization for minimally invasive ab interno glaucoma surgery, following its 510(k) clearance in April 2025
• In February 2025, Alcon announced the US launch of Voyager DSLT, the first fully automated direct selective laser trabeculoplasty device for treating glaucoma and ocular hypertension as a first-line therapy. The FDA-cleared system eliminates the need for a gonio lens and manual aiming, aiming to expand access to laser treatment through improved efficiency, safety, and ease of adoption
• In July 2024, Alcon completed the acquisition of BELKIN Vision for an US$81 million, adding Direct Selective Laser Trabeculoplasty (DSLT) technology to expand its glaucoma portfolio with a first-line laser therapy. The acquisition strengthened Alcon’s position across pharmaceuticals, implantable, and laser treatments while supporting the global shift toward first-line SLT use in glaucoma management
• In April 2023, Ciliatech raised US$4.1 million (€3.5 million) in Series A funding to advance development of its disruptive glaucoma implant, the Cilio-scleral Inter-positioning Device (CID). The funding supports R&D, expanded clinical trials across Europe, and regulatory activities

To learn more about this report, download the PDF brochure

Surgery Type Segment Outlook

Conventional glaucoma surgery, which is regarded as the global standard of care within the field of advanced and/or refractory glaucoma continues to be the largest segment of the glaucoma surgery devices market due to its well-documented long-term success and significant acceptance throughout the world. In contrast, the MIGS segment is the fastest-growing type of glaucoma surgical device due to its exceptional safety characteristics along with the reduction in the length of recovery period and is typically used to treat patients with early to moderate-stage glaucoma. Although laser surgery has a moderate share of the overall market and is typically used as a supplement or alternative to traditional surgery, it has a comparatively slower growth rate than MIGS or conventional surgery devices.

Regional Outlook: North America expected to hold a major share in the glaucoma surgery devices market

North America represents the largest regional segment in the glaucoma surgery devices market attributed to a high rate of diagnosed cases, strong reimbursement policies, quick uptake of new technology, and numerous global device manufacturers. The Asia-Pacific region is expected to grow the fastest due to an aging population increasing knowledge about glaucoma, improvements in healthcare systems, and increasing access to ophthalmic service providers within many emerging nations. Europe represents a significant market share and is very much established. Latin America and the Middle East & Africa are experiencing growth, but it is incremental due to ongoing developments in the medical care delivery system.

Competitive Landscape Analysis

The global glaucoma surgery devices market is marked by the presence of established and emerging market players such as Alcon Inc. (Switzerland); Glaukos Corporation (US); Johnson & Johnson (US); AbbVie Inc. (US); Santen Pharmaceutical Co., Ltd. (Japan); New World Medical (US); Lumenis Be Ltd. (Israel); Carl Zeiss Meditec AG (Germany); Ziemer Ophthalmic Systems AG (Switzerland); and Iridex Corporation (US); among others. Some of the key strategies adopted by market players include new product launches and approvals, acquisitions, investments, and strategic partnerships and collaborations.

Get a sample report for competitive landscape analysis

Report Scope

Global Glaucoma Surgery Devices Market Segmentation

This report by Medi-Tech Insights provides the size of the global glaucoma surgery devices market at the regional- and country-level from 2024 to 2031. The report further segments the market based on product, surgery type, and end user.

Market Size & Forecast (2024-2031), By Product, USD Billion

• Glaucoma Drainage Device
  • Valved Devices
  • Non-Valved Devices
  • Other Glaucoma Drainage Device
• Traditional Surgical Devices
  • Scalpel
  • Forceps
  • Ophthalmic Scissors
  • Sutures
  • Microcatheter
  • Other Traditional Surgical Devices
• Glaucoma Implants and Stents
• Laser Surgical Devices
• Other Products

Market Size & Forecast (2024-2031), By Surgery Type, USD Billion

• Minimally Invasive Glaucoma Surgery (MIGS)
• Conventional Glaucoma Surgery
• Laser Surgery

Market Size & Forecast (2024-2031), By End User, USD Billion

• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgery Centers (ASCs)
• Other End Users

Market Size & Forecast (2024-2031), By Region, USD Billion

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Related Reports:

Global Vision Impairment Devices Market Size & Trends Report Segmented by Device Type (Low Vision, Blindness, Mobility, Daily Living Aids), End User (Special Needs Schools/Institutions, Enterprises/Social Organizations, Visually Impaired Individuals), Forecast to 2030

Global Ophthalmology Drugs Market Size & Trends Report Segmented by Drug Class (Anti-allergy, Anti-inflammatory, Non-steroidal), Product Type (Prescription Drugs, OTC), Dosage Form (Gels, Capsules & Tablets, Ointments), Disease & Regional Forecast to 2030

Global Ophthalmic Products Market Size & Trends Report, Segmented by Product Type (Surgical Devices, Consumables, Implantable Devices, Vision Care, Contact Lens), Application (Cataract, Glaucoma), End User (Hospitals, Ophthalmic Clinics, ASCs), & Regional Forecasts to 2029